Effect of Piperacillin/tazobactam Restriction on Usage and Rates of Acute Renal Failure.

Effect of Piperacillin/tazobactam Restriction on Usage and Rates of Acute Renal Failure. J Med Microbiol. 2015 Dec 21; Authors: Lorenz MA, Moenster RP, Linneman TW Abstract A piperacillin/tazobactam (PT) restriction was initiated at our institution on 15 July 2012 requiring clinical pharmacy or infectious diseases approval for durations exceeding 72 hours. A retrospective review was undertaken to determine if this restriction decreased PT usage and/or rates of acute renal failure (ARF) (defined as a 50% increase or 0.5 mg/dL increase in serum creatinine from baseline). Patients prescribed at least 1 day of PT with a creatinine clearance (CrCl) >39 mL/min at the time of initiation in the 3 months prior to the restriction were compared to patients in the 5 months after restriction implementation. Overall, 115 unique patients were included in the pre-implementation group and compared to 117 unique patients in the post-implementation group. The pre-implementation group received an average of 5.22 days of PT, compared to 4.71 days in the post-implementation group (P=0.224). Ten percent (12/115) of patients in the pre-implementation group developed ARF compared to 9.16% (11/120) of patients in the post-implementation group (P=0.0309). Ninety five patients in the pre-implementation group and 91 in the post-implementation group received combination therapy with vancomycin. ARF occurred in 11.6% (11/95) of those in the pre-implementation g...
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research